| Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia (NCT05118230) | Novartis Pharmaceuticals | 2021-12-09 |
| A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A (NCT05131997) | Addpharma Inc. | 2021-11-16 |
| Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage (NCT04849000) | Jiangsu HengRui Medicine Co., Ltd. | 2021-04-23 |
| SHR - 1209 Treatment Efficacy and Safety of the Patients With Hypercholesterolemia Ⅲ Period Clinical Research (NCT04844125) | Jiangsu HengRui Medicine Co., Ltd. | 2021-04-14 |
| Study to Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia (NCT05206578) | Ahn-Gook Pharmaceuticals Co.,Ltd | 2020-12-08 |
| Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022 (NCT06448962) | Addpharma Inc. | 2020-10-22 |
| Compare the Efficacy and Safety of 1PC111 With Pitavastatin and Ezetimibe in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia (NCT04643093) | Orient Pharma Co., Ltd. | 2020-08-01 |
| To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia (NCT04659070) | Hanlim Pharm. Co., Ltd. | 2020-07-15 |
| To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia (NCT04584736) | JW Pharmaceutical | 2019-06-11 |
| Effect of Probiotics on Lipid Management (NCT03952169) | Sun Yat-sen University | 2019-05-12 |
| Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia (NCT03433755) | Amgen | 2019-05-09 |
| Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia (NCT03413462) | Zhejiang Hisun Pharmaceutical Co. Ltd. | 2016-04-12 |
| Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary Hypercholesterolemia (NCT03464682) | Zhejiang Hisun Pharmaceutical Co. Ltd. | 2015-02-28 |
| Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers (NCT02941848) | Hanmi Pharmaceutical Company Limited | 2014-11-01 |
| Efficacy and Safety of a Generic Rosuvastatin in a Real-world Setting (NCT03516955) | Hikma Pharmaceuticals LLC | 2014-11-01 |
| Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia (NCT03571087) | Hanlim Pharm. Co., Ltd. | 2014-09-01 |
| Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia (NCT02445352) | Alvogen Korea | 2014-07-01 |
| Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia (NCT02205606) | Hanmi Pharmaceutical Company Limited | 2014-06-01 |
| A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia (NCT02087917) | Zhejiang Hisun Pharmaceutical Co. Ltd. | 2014-03-01 |
| Efficacy Study of Vitamin D and Statins to Treat Hypercholesterolemia (NCT02009787) | Shi Yang | 2013-12-01 |
| Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen (NCT01879319) | Amgen | 2013-07-11 |
| Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen (NCT01849497) | Amgen | 2013-04-18 |
| Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) (NCT01335997) | Merck Sharp & Dohme LLC | 2011-05-01 |
| Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) (NCT01274559) | Merck Sharp & Dohme LLC | 2011-03-01 |
| A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118) (NCT01294683) | Merck Sharp & Dohme LLC | 2011-02-04 |
| Effects of Prescription Omega-3 on LDL-C in Primary Hypercholesterolemia (NCT00746811) | Provident Clinical Research | 2010-01-01 |
| A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED) (NCT01012219) | Merck Sharp & Dohme LLC | 2009-11-01 |
| Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675) (NCT00941603) | Merck Sharp & Dohme LLC | 2009-06-29 |
| Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED) (NCT00724477) | Organon and Co | 2007-10-01 |
| Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067) (NCT00479388) | Merck Sharp & Dohme LLC | 2007-07-01 |
| MK-0524B Lipid Study (MK-0524B-063) (NCT00479882) | Merck Sharp & Dohme LLC | 2007-06-15 |
| Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia (NCT00776321) | Karo Bio AB | 2006-09-01 |
| Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED) (NCT00704535) | Organon and Co | 2006-03-01 |
| Lipid Efficacy Study (0524B-022)(COMPLETED) (NCT00269217) | Merck Sharp & Dohme LLC | 2006-01-01 |
| Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels (NCT00249249) | Kowa Research Europe | 2005-10-01 |
| A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173) (NCT03882905) | Organon and Co | 2001-01-31 |